Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Depreciation & Amortization
Zealand Pharma A/S
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Depreciation & Amortization
kr25.8m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
16%
|
|
|
Genmab A/S
CSE:GMAB
|
Depreciation & Amortization
kr413m
|
CAGR 3-Years
19%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Depreciation & Amortization
€17.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
22%
|
CAGR 10-Years
43%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Depreciation & Amortization
kr663.4m
|
CAGR 3-Years
20%
|
CAGR 5-Years
63%
|
CAGR 10-Years
31%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Depreciation & Amortization
kr2.4m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
24%
|
|
|
Saniona AB
STO:SANION
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Depreciation & Amortization?
Depreciation & Amortization
25.8m
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Depreciation & Amortization amounts to 25.8m DKK.
What is Zealand Pharma A/S's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
16%
Over the last year, the Depreciation & Amortization growth was 3%. The average annual Depreciation & Amortization growth rates for Zealand Pharma A/S have been -14% over the past three years , 14% over the past five years , and 16% over the past ten years .
You don't have any saved screeners yet